Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CRHBP | P24387 | 1/20 | 0.34 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | TET3 | O43151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | FBXL19 | Q6PCT2 | 1/20 | 0.30 |
| ▸ | CXXC5 | Q7LFL8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10609158 | 0.76 | ALDH1A1 (0.44) | NPSR1ALDH1A1POLBFAAHNAAA | |
| SCHEMBL10434774 | 0.76 | — | — | |
| SCHEMBL10434775 | 0.73 | — | — | |
| SCHEMBL1323848 | 0.73 | — | — | |
| SCHEMBL2279803 | 0.73 | ACHE (0.33) | TSHRACHETET3KMT2AFBXL19 | |
| Hydrochloric Acid SCHEMBL11592382 | 0.71 | NPSR1 (0.53) | NPSR1ALDH1A1POLBFAAHNAAA | |
| SCHEMBL134244 | 0.71 | — | — | |
| SCHEMBL6639420 | 0.71 | — | — | |
| SCHEMBL13484119 | 0.71 | — | — | |
| SCHEMBL4194016 | 0.71 | GAA (0.40) | NPSR1ALDH1A1POLBFAAHNAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0240370-B1 | N-ACYL SUBSTITUTED CYCLIC UREAS | SEQUA CORPORATION (US) | 1991-03-20 | — | — | EP | claimed |
| US-4766221-A | N-acyl substituted cyclic ureas | SEQUA CHEMICALS, INC. (US) | 1988-08-23 | — | — | US | claimed |
| EP-0240370-A2 | N-acyl substituted cyclic ureas | SEQUA CORPORATION (US) | 1987-10-07 | — | — | EP | claimed |
| US-3931216-A | Process for the manufacture of 2-arylamino-2-imidazoline derivatives and their salts | BOEHRINGER INGELHEIM GMBH (DT) | 1976-01-06 | — | — | US | claimed |
| US-20080057096-A1 | Comprising stent body, first layer applied over stent body comprising a therapeutic substance and second layer applied over first layer comprising a fluoride-containing hydrophilic water insoluble crosslinked resin; biocompatible layer leaches fluoride to provide further therapy to patient | DEN-MAT CORPORATION | 2008-03-06 | — | — | US | disclosed |
| US-20080057096-A1 | Comprising stent body, first layer applied over stent body comprising a therapeutic substance and second layer applied over first layer comprising a fluoride-containing hydrophilic water insoluble crosslinked resin; biocompatible layer leaches fluoride to provide further therapy to patient | DEN-MAT CORPORATION | 2008-03-06 | — | — | US | disclosed |
| EP-0240370-B1 | N-ACYL SUBSTITUTED CYCLIC UREAS | SEQUA CORPORATION (US) | 1991-03-20 | — | — | EP | disclosed |
| US-4766221-A | N-acyl substituted cyclic ureas | SEQUA CHEMICALS, INC. (US) | 1988-08-23 | — | — | US | disclosed |
| EP-0240370-A2 | N-acyl substituted cyclic ureas | SEQUA CORPORATION (US) | 1987-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080057096-A1 | Comprising stent body, first layer applied over stent body comprising a therapeutic substance and second layer applied over first layer comprising a fluoride-containing hydrophilic water insoluble crosslinked resin; biocompatible layer leaches fluoride to provide further therapy to patient | FGB, CSTB, FGFR2 | NPSR1 773/4885ALDH1A1 2251/4885POLB 3777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.